Biovest Joins in the Formation of the Joint U.S.–Norway Cancer Research Program, a Collaborative Effort with Plans to Present to National Cancer Institute and the U.S. Military Healthcare System

TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that Biovest has been designated one of the charter members of the Joint U.S.–Norway Cancer Research Program, a collaboration among leading pharmaceutical and biotechnology companies and research organizations with the vision of transforming world-class cancer diagnostics and treatments to improve and extend the lives of cancer patients.